JP2003226650A - Medicinal composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicinal composition having excellent activities for preventing and treating hangover, especially a composition for gastroenteropathy, a composition for preventing and treating the hangover, a composition for promoting ingestion of alcohol, and a composition for inhibiting decrease of a blood glucose level caused by the alcohol ingestion. <P>SOLUTION: This medicinal composition contains a Scutellaria root or an extract thereof, cork tree bark or an extract thereof, Coptis Rhizome or an extract thereof, turmeric or an extract thereof and ginger or an extract thereof. <P>COPYRIGHT: (C)2003,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a pharmaceutical composition, particularly a composition for gastrointestinal illness, a composition for preventing / treating hangover, a composition for promoting alcohol disappearance, and a composition for suppressing a decrease in blood glucose level by alcohol intake. It relates to a composition.

[0002]

2. Description of the Related Art A number of studies have been conducted so far on the cause of hangover, which is largely due to excessive intake of alcohol. It is said that the cause is vomiting due to acetaldehyde which is an ethanol metabolite, nausea, headache, palpitations and decrease in blood glucose level due to ethanol intake, but there are still many unclear points. To date, various drugs (eg, for the prevention and treatment of hangovers)
Animal bile (see Patent Document 1), protease-treated pork (see Patent Document 2), and ethanolamine derivative (see Patent Document 3) are known, but none of them have satisfactory effects. It was

[0003]

[Patent Document 1] JP-A-6-279298

[Patent Document 2] Japanese Patent Laid-Open No. 11-276116

[Patent Document 3] Japanese Patent Laid-Open No. 2002-104961

[0004]

DISCLOSURE OF THE INVENTION The present invention provides a pharmaceutical composition excellent in prevention and treatment of hangover, particularly a gastrointestinal composition.
An object of the present invention is to provide a composition for preventing / treating hangover, a composition for promoting alcohol disappearance, and a composition for suppressing a decrease in blood glucose level due to alcohol intake.

[0005]

The present invention has the following constitution. 1) Ougon or its extract, Oat or its extract, Ouren or its extract, Turmeric or its extract,
And a pharmaceutical composition containing ginger or an extract thereof. 2) The pharmaceutical composition according to 1) above, which further contains carrot or an extract thereof. 3) The pharmaceutical composition according to 1) or 2) above, which further contains bile acid. 4) The pharmaceutical composition according to 3) above, wherein the bile acid is ursodeoxycholic acid. 5) The pharmaceutical composition according to any one of 1) to 4) above, wherein a part or all of Oataku and Oren are replaced with Colombo. 6) A composition for gastrointestinal diseases, which is characterized in 1) to
The pharmaceutical composition according to any one of 5). 7) The pharmaceutical composition according to any one of 1) to 5) above, which is a composition for preventing / treating hangover. 8) The pharmaceutical composition according to any one of 1) to 5) above, which is a composition for promoting alcohol disappearance. 9) The pharmaceutical composition according to any one of 1) to 5) above, which is a composition for suppressing a decrease in blood glucose level by ingesting alcohol. 10) The pharmaceutical composition according to any one of 1) to 9) above, wherein the dosage form is an oral preparation. 11) The pharmaceutical composition according to any one of 1) to 9) above, wherein the dosage form is a liquid or a pill.

The pharmaceutical composition of the present invention (hereinafter also referred to as the composition of the present invention) essentially contains sorghum, sorghum, sardine, turmeric and ginger, and preferably contains bile acid and carrot. However, as a result of the finding that this composition has the following effects on the physiological phenomenon which is considered to be particularly related to hangover, as a result, the prevention / treatment of gastrointestinal disease and hangover, and the disappearance of alcohol. It was found to be effective in promoting and suppressing the decrease in blood glucose level by alcohol intake. Hypoglycemic inhibitory effect (alcohol intake lowers blood glucose level and causes weakness, but suppresses this hypoglycemic value) Metabolism promoting action of ethanol ADH and ALDH activity lowering inhibitory action in the liver Antiulcer action in gastric mucosa Enzyme activity, for example, MPO activity promotion inhibitory effect and SOD activity decrease inhibitory effect The above-mentioned effects of the composition of the present invention are not limited to those dependent on alcohol intake. For example, the antiulcer action and the like are not limited to those caused by alcohol intake. Further, it was found that turmeric and / or ginger has an alcohol disappearance promoting action, and thus an alcohol disappearance promoting agent containing turmeric and / or ginger can be provided. Furthermore, it was found that turmeric exhibits a gastric mucosa protective action, and a gastric mucosa protective agent containing turmeric can also be provided.

Next, each component of the composition of the present invention will be described. Scutellaria baicalensis is a root excluding the pericardium of Lamiaceae, and is known to have antibacterial, sedative, bile, and anti-inflammatory effects. Owakaku is a bark excluding the pericarp of Rutaceae or other plants of the same genus, and is known to have antibacterial, astringent, anti-inflammatory, stomachic and diuretic effects. Coptis chinensis (Huangren) is a rhizome excluding the roots of the buttercup family Coptis genus Orchid and other plants of the same genus, and is known to have antibacterial, anti-inflammatory, stomachic and choleretic actions. Turmeric is a rhizome of the ginger family Turmeric, and is known to have stomachic and bile effects. Ginger is a rhizome of ginger and is known to have stomachic, analgesic and anti-emetic effects. A carrot (carrot) is a root obtained by excluding the fine roots of Panax ginseng of the Araliaceae family or lightly blanched, and is known to have prosthetic, tonic and sedative effects.

Bile acids are contained in bile and the like, and examples thereof include cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, dehydrocholic acid and the like. Used in combination. Of these, ursodeoxycholic acid is preferred. Jateorhiza columba M
Colombo that has crossed the roots of iers (Menispermaceae) can be used in place of a part or all of Oataku and / or Ouren contained in the composition of the present invention as a substitute for Oataku, Ouren (this is Oataku, Known as similar medicines of ouren.).

The present invention relates to a pharmaceutical composition containing the above-mentioned various crude drugs. The form of the crude drug can be freely adjusted as required, and it can be cut or crushed into small pieces or lumps. Alternatively, it can be ground into powder. The powder of crude drug is generally called "crude drug powder". For example, the powder of "Ginger" is called "Ginger powder".

[0010] In the present invention, the crude drug extract means a liquid leached by adding an appropriate leaching agent to the crude drug, or a liquid obtained by concentrating the leaching liquid, specifically, "extract" and "tincture".
Etc. can be mentioned. For example, as an extract of “Ouren”, “Ouren extract”, “Ouren tincture” and the like can be mentioned. As the leaching agent, methanol,
Lower monohydric alcohols such as ethanol and n-butanol,
Ethylene glycol, propylene glycol, 1,3-
Lower polyhydric alcohols such as butylene glycol and glycerin, ethers such as diethyl ether, ketones such as acetone and ethyl methyl ketone, esters such as ethyl acetate, halogenoalkanes such as dichloromethane and chloroform, benzene, toluene, etc. Aromatic hydrocarbons, water, etc. can be mentioned. These leaching agents may be used alone, or may be used by mixing two or more kinds, or may be heated and used. A known method (for example, the method described in the Japanese Pharmacopoeia) may be used for producing the extract.

Further, dried "extract" is also included in the extract of the present invention, which is usually called "dry extract",
For example, the dried extract of "Ougon" is called "Ougon dried extract". A known method may be used for producing the dried extract. In general, the same effect can be obtained in any form of crude drug as long as the source is the same.

The composition of the present invention can be administered orally or parenterally, preferably orally. The dosage form of the preparation for oral administration (oral preparation) includes extract, elixir, syrup, tincture, limonade and other liquids and capsules, granules,
Examples include solid ones such as pills, powders and tablets. The formulation containing the composition of the present invention can be formulated into various dosage forms by known formulation techniques, and appropriate formulation additives can be added to the formulation. Specific examples of formulation additives include excipients, binders, disintegrating agents, suspending agents, preservatives, antioxidants, corrigents and the like. The formulation additive needs to be harmless to the living body such as the human body at the dose of the formulation, and it must also not interfere with the effect of the active ingredient.

For example, excipients include lactose, corn starch, crystalline cellulose and the like, binders include gum arabic powder, dextrin, carboxymethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol and the like, and disintegrants. Examples include corn starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, crospovidone, and the like, suspending agents include sodium alginate, polyvinylpyrrolidone, and the like, and preservatives include ethyl paraoxybenzoate, butyl paraoxybenzoate, and the like. Examples of the antioxidant include ascorbic acid and tocopherol, and examples of the corrigent include sucrose, honey, aspartame, stevia, dipotassium glycyrrhizinate, and the like.

The daily dose of each crude drug of the composition of the present invention in terms of the original drug is as follows.
Various selections can be made according to the symptoms. Amber is usually 5
0 mg to 15 g and 100 mg to 2500 mg are preferable. Ouren is usually 25 mg to 10 g, 50 mg to
2500 mg is preferred. Oat is usually 25 mg
-10g and 50mg-2500mg are preferred. Colombo is usually 25 mg to 10 g, 50 mg to 2500 m
g is preferred. Turmeric is usually 25 mg to 100 g,
50 mg to 5000 mg is preferable. Showkyo is
Usually, 10 mg to 10 g and 50 mg to 2500 mg are preferable. Carrot is usually 50 mg to 15 g, 100
mg to 5000 mg is preferred. Bile acids are usually 0.
5 mg-300 mg and 1 mg-100 mg are preferable.

The composition ratio of the composition of the present invention should not be limited, but 0.5 to 2 parts by mass and 0.5 to 2.5 parts by weight of laurel per 1 part by mass of eugon in terms of the crude drug.
Examples include 2 parts by mass, turmeric 2.5 to 15 parts by mass, ginger 0.5 to 2 parts by mass, carrot 0.3 to 2 parts by mass, and bile acid 0 to 1 parts by mass. In addition, 0.7 parts of Oren are added to 1 part by mass of Ougon in terms of drug substance.
1.5 parts by mass, Oataku 0.7 to 1.5 parts by mass, turmeric 3.0 to 12 parts by mass, ginger 0.7 to 1.5 parts by mass, carrot 0.4 to 1.5 parts by mass, bile Acid 0-0.2
It is preferable that the composition is mixed in an amount of parts by mass, and further, a composition in which the compounding ratio of Ougon, Oren, Oataku, Turmeric, Ginger, bile acid and carrot in the ratios described in Formulation Examples 1 and 2 below is particularly preferable. . Further, in the composition of the present invention, sodium hydrogen carbonate, magnesium metasilicate aluminate, synthetic hydrotalcite, synthetic aluminum silicate, aldioxa, sucralfate, cetraxate hydrochloride, citrus or its extraction, within the range that does not impair the effects of the present invention. Substance, cinnamon or extract thereof, Engosaku or extract thereof, assembly or extract thereof, fennel or extract thereof, borei or extract thereof, licorice or extract thereof, glycyrrhizic acid, ammonium glycyrrhizinate, dipotassium glycyrrhizinate, glycyrrhizin Monoammonium acid, carnitine chloride and the like may be further added.

To take the composition of the present invention orally, 1
It can be taken in 4 divided doses.
Examples include before meals, between meals, after meals, and before bedtime. The dose (administration) amount can be appropriately increased or decreased depending on age, sex, body weight and symptoms. The composition of the present invention is excessively swallowed, sneezing (hangover / nausea), vomiting, loss of appetite, leaning, stomach weakness, digestion promotion, overeating, chest holding, heartburn, bloating stomach / abdomen due to indigestion. It is effective for feeling, indigestion, various pains, and lowering of blood sugar level due to alcohol intake.

[0017]

EXAMPLES The present invention will be described in more detail below with reference to the composition of the present invention and test examples thereof.

Test Example 1 Effect on Blood Ethanol Concentration after Administration of Ethanol (Alcohol Dissipation Promoting Effect) Method A group of 10 to 12 male ddy mice fasted overnight was prepared, and the constituent herbal medicines shown below were added. The ratio of test drug was orally administered at 0.2 ml / animal. In addition, 0.2 ml / animal of purified water was administered to the control group (the same applies hereinafter). 30 minutes after the administration, 0.4 ml / animal of 30% was orally administered. 0.7 ml of blood was collected from the animal using a 500 U heparin-containing syringe 1, 3 and 6 hours after the administration of ethanol. Blood collection 0.4 ml
To this, 0.4 ml of cold 1 mol / l-perchloric acid was added and mixed, and the mixture was allowed to stand under ice cooling for 15 minutes and then centrifuged, and the supernatant was collected to measure the ethanol concentration. That is, 3 ml of 0.2 mol / l-glycine buffer (pH 10.6) was added to 0.1 ml of the supernatant, and NAD (5 mg / ml) was added to 0.05 ml.
Was added and allowed to stand at 25 ° C for 5 minutes, then the absorbance at 340 nm (E ₀ )
Was measured. Then, add 0.05 ml of ADH (500 U / ml), and add 10
After a minute, the absorbance (E ₁ ) at 340 nm was measured again, and (E ₁ −E ₀ ).
The difference in absorbance was determined, and the concentration of ethanol in blood was determined using the calibration curve. Data obtained 6 hours after ethanol administration are shown in Table 1.

Test drug prescription A-1: Ginger prescription A-2: Yellow ginger, yellow ginger, Huanglian (1: 1: 1) Prescription A-3: Ginger, ginger, yellow ginger, Huanglian (1: 1) : 1:
1) Among the test drugs, yellow orchid and yellow oak were used yellow orchid extract (commercial product) and yellow oak extract (commercial product), and yellow corn was dried yellow corn extract (commercial product). Dose 300 in Table 1
(Mg / kg) means, for example, in the case of the prescription A-2, in terms of a crude drug, yellow rice 300 (mg / kg), yellow oak 300
(Mg / kg), that means that the one prepared to contain Huanglian 300 (mg / kg) was administered,
The same applies to this test example and thereafter. result

[0020]

[Table 1]

From the above-mentioned table, it was shown that the formulation A-3, in which yellow ginger, yellow oak, and yellow reed were mixed with ginger, had a higher alcohol elimination effect from blood than the formulation A-2 containing no ginger.
It was also found that ginger newly has an alcohol-dissipating (promoting) action, and that the action is enhanced when used in combination with the formulation A-2.

Test Example 2 Action and Method on Blood Glucose Level after Administration of Ethanol In the same manner as the above method, the test drug having the following constituent crude drugs and compounding ratios was orally administered, and collected 6 hours after ethanol administration. Centrifugated 0.3 ml of blood sample and obtained the supernatant 2
Diluted water (0.2 ml) was added to 0 μl for mixing and dilution. This liquid 0.025
Measurement kit using glucose oxidase per ml
The blood glucose level was measured using (Glucose measurement test-B Wako). The results are shown in Table 2. Test drug prescription A: ginger prescription B: yellow ginger, yellow oak, yellow lantern (1: 1: 1) Prescription C: ginger, yellow vine, yellow oak, yellow lantern (1: 1: 1: 1) Results

[0023]

[Table 2]

As is clear from the above table, alcohol intake has the effect of lowering the blood glucose level, and the formulation B promotes the lowering action, but the formulation C in which ginger is mixed with this formulation B is excellent. The inhibitory effect on the decrease of blood glucose level by alcohol intake was shown.

(Test Example 3) Inhibitory activity of hepatic drug-metabolizing enzyme (alcohol-metabolizing enzyme) activity after administration of ethanol Method: 10--12 male ddy mice fasted overnight were used as (Test Example 1). 30% ethanol was orally administered at 0.4 ml / animal 30 minutes after the administration of the indicated crude drug and the test drug having the compounding ratio. One hour after the administration of ethanol, the liver was removed and cold water was added to homogenate. Homogenate solution is 0 ℃, 10,0
Centrifugation was performed at 00 rpm for 30 minutes, and the supernatant was collected to give an enzyme solution. After adding a phosphate buffer (pH 8.3) containing 25 mg / ml NAD to this enzyme solution, 10 μl of 10% ethanol or 10% acetaldehyde was added, and the time change of the absorbance at 340 nm was measured using a spectrophotometer. . The enzyme activity was expressed as the specific activity per 1 mg of protein, where the change in absorbance per minute was 0.001 as 1 U. The results are shown in Table 3. ·result

[0026]

[Table 3]

From the above table, it can be seen that Formulation A-3 effectively suppresses the decrease in ADH and ALDH activity and is effective in the prevention and treatment of hangover.

Test Example 4 Anti-ulcer action (protective effect on gastric mucosa) and enzyme Suppressing MPO activity promotion in gastric mucosa and S
Suppression of OD activity reduction Six-week-old male ddy mice were fasted in a cage made of wire mesh for 18 hours and then orally administered (Test Example 1) and the test drug consisting of the constituent crude drug and compounding ratio shown below (n = 19). 30 ml after administration of test drug, 0.2 ml of 60% ethanol containing 150 mM hydrochloric acid
Oral administration was carried out. 90 minutes after the administration of ethanol, the animal was sacrificed by cervical dislocation, the abdomen was opened, and the stomach was excised. 2 stomachs removed
One group was injected with 1 ml of 10% formalin, fixed for 30 minutes, incised in the bay, and the ulcer occurring in the fundus was measured (n = 9). In addition, for the stomach of the other 1 group, the fundus was minced and homogenized by adding 1 ml of cold water at 0 ° C and 10,000 rpm.
After centrifuging for 30 minutes, the supernatant was collected to measure myeloperoxdase (MPO) and superoxide disumutase (SOD) activities (n = 10). The enzyme activity was expressed as the specific activity per mg of protein. MPO activity is 1.6 m according to the method of Suzuki et al. (Anal. Biochem. 132, 345-352, 1983).
5 μl of enzyme solution was added to a solution consisting of M tetramethylpentyne, 15 mM hydrogen peroxide solution, 80 mM phosphate buffer (pH 5.4), and 8% dimethylformamide 40% PBS, and incubated at 37 ° C. for 20 minutes, then 20
The reaction was stopped by adding 0 mM acetic acid (pH 3.0). The absorbance at 650 nm of this solution was measured using a microplate reader. The enzyme activity was expressed as the specific activity per 1 mg of protein, where the change in absorbance per minute was 0.001 and 1 U was defined as 1 U. SOD activity was determined by the method of Oyanagi (Anal. Biochem. 142, 290).
-296, 1984), 0.25 mM hydroxylamine hydrochloride,
After adding 10 μl of enzyme solution to 20 mM phosphate buffer (pH 8.2) containing 0.25 mM xanthine and 0.025 mM EDTA, 100 μl of xanthine oxidase (25 U / ml) was added, and after reacting at 37 ° C for 45 minutes, ethylenediamine and sulfanil The reaction was stopped by adding 100 μl of acetic acid solution consisting of acid, and then 570 nm
The absorbance at was measured using a microplate reader. For the enzyme activity, a calibration curve was prepared from a bovine serum SOD standard product, and the specific activity per mg of protein was determined from it. The amount of protein was measured by the Burett method. The results are shown in Tables 4-6. Test drug prescription A-4: depression gold prescription A-5: ginger, yellow rice, yellow oak, yellow ream, depression gold (1:
1: 1: 1: 7.5) As the gold, gold extract (commercially available) was used. ·result

[0029]

[Table 4]

[0030]

[Table 5]

[0031]

[Table 6]

When hydrochloric acid-ethanol was administered, a ulcer accompanied by bleeding occurred in the glandular stomach in the control. However, those administered with the formulations A-1, A-2, A-4 and A-5 showed excellent anti-ulcer action. Further, the same formulation showed an action of suppressing the enhancement of MPO activity seen in the control. further,
For Formulations A-1 and A-2, SOD found in control
It was found to have an action of decreasing the activity. Therefore, it was revealed that the formulations A-1, A-2, A-4 and A-5 were effective in protecting the gastric mucosa.

Test Example 5 Action on Blood Ethanol Concentration after Administration of Ethanol (Promoting Alcohol Dissipation) Method 5 ddy male male mice (body weight around 30 g) aged 5 weeks after fasting for 18 hours were shown as follows. Oral administration of the constitutive crude drug and the test drug in the compounding ratio. Thirty minutes after the administration of the test drug, 30% ethanol was orally administered at 0.4 ml / animal. The control group was orally administered with purified water at 0.4 ml / animal. Blood was collected from the mice 1, 2, 3, 4 and 5 hours after the administration of ethanol. 0.4 ml of 1N perchloric acid was added to 0.4 ml of the blood sample, mixed well, centrifuged, and the supernatant was collected to obtain a blood ethanol concentration measurement sample. The ethanol concentration was measured by adding 3 ml of 0.1 M glycine buffer (pH 10.4) to 0.5 ml of the sample solution and 0.5 mg /
0.1 ml of β-NAD (diphosphopyridine nucleotide oxidation type) at a concentration of ml was added and mixed well, and 340 nm
The absorbance (A ₀ ) at was measured using a spectrophotometer. Then, 0.1 ml of 250 U / ml alcohol dehydrogenase solution was added and mixed, and the mixture was allowed to stand for 20 minutes, and then again 34
The absorbance (A ₁ ) at 0 nm was measured to calculate the difference in absorbance (A ₁ −A ₀ ). This operation was performed in an environment of 25 ° C. For ethanol concentration, an ethanol solution having a known concentration was used to prepare a calibration curve by the same operation, and the blood concentration was calculated using the calibration curve. Data obtained 5 hours after ethanol administration are shown in Table 7. Test drug prescription D: ginger, yellow rice, yellow oak, yellow ream, euphoria (1: 1:
1: 1: 7.5) Prescription E: ginger, yellow rice, yellow oak, yellow ream, beef gall (1: 1:
1: 1: 0.5) Results

[0034]

[Table 7]

From the above table, ginger, yellow rice, yellow oak, yellow ream,
It was shown that the formulation D containing euphoria had a higher alcohol elimination effect from the blood than the formulation E containing beef gall in place of euphoria. From this, it was found that tsukin had an alcohol erasing (promoting) action.

(Formulation Example 1) A pill containing the composition of the present invention containing the following components as main components was produced. (In the daily dose (9 rounds)) Ougon dry extract 50 mg (300 mg as an active drug) Oat dry extract 50 mg (300 mg as an active drug) Ouren extract 50 mg (300 mg as an active drug) Carrot powder 150 mg Ginseng powder 300 mg Turmeric extract 150 mg ( 2250 mg as a crude drug) Ursodeoxycholic acid 45 mg

(Formulation Example 2) A liquid preparation containing the composition of the present invention containing the following components as main components was prepared. (In a daily dose (60 ml)) Scutellaria extract 75 mg (300 mg as a crude drug) Scutellaria extract 0.3 ml (300 mg as a crude drug) Oat extract 100 mg (300 mg as a crude drug) Pheasant extract 200 mg (1000 mg as a crude drug) Carrot flow extract 0.2 ml (200 mg as a crude drug) Ginger extract 0.6 ml (600 mg as a crude drug) Keihi tincture 1.0 ml (200 mg as a crude drug) Turmeric flow extract 1.0 ml (1000 mg as a crude drug) Carnitine chloride 120 mg

(Test Example 6) Administration Test Ten healthy adult males were used as test subjects and divided into two groups (groups A and B) of 5 persons each. Group A was asked to take 3 pills of Formulation Example 1 at 6 pm, and 30 minutes after taking the drug, an amount of alcohol (beer, beer, I had dinner with sake, whiskey, shochu). 1 hour after the start of eating and drinking and immediately after the completion of eating and drinking, 3 pills of Formulation Example 1 were taken again, the patient was put to bed at 11:00 pm, and subjective symptoms were examined at 7:00 am the next morning. The other group B was allowed to have dinner as in the case of group A without taking the pills, and the subjective symptoms were examined the next morning. The test was conducted again one week later, but for group B, formulation example 1 at 6 pm
The test was conducted under the same conditions as the previous time, except that 3 pills of No. 3 were taken and the group A was not taken. As a result, when the pills of Formulation Example 1 were not taken, 8 out of 10 people still suffered from hangover symptoms such as "become sick, headache, heavy stomach" No hangover symptoms were observed in any of the 10 patients when taking the pill No. 1 (Table 8).
reference).

[0039]

[Table 8]

As a result of the subjective symptom examination, it was found that when the pills of Formulation Example 1 containing the composition of the present invention were taken, the recovery of hangover symptoms was greater than when the above formulation was not taken.

[0041]

INDUSTRIAL APPLICABILITY The present invention, which contains a specific herbal medicine component, exerts effects for improving gastrointestinal diseases, preventing and treating hangover, promoting alcohol disappearance, and suppressing lowering of blood glucose level by alcohol intake.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61K 9/20 A61K 9/20 31/575 31/575 A61P 1/04 A61P 1/04 39/02 39 / 02 (72) Tsutomu Amemiya Tsutomu Amemiya 3-14-10 Nihonbashi, Chuo-ku, Tokyo Daiichi Pharmaceutical Co., Ltd. (72) Inventor Noritaka I, 1-1-16 Kitakasai, Edogawa-ku, Tokyo Daiichi Pharmaceutical Co., Ltd. Tokyo F-term in R & D center (reference) 4C076 AA12 AA36 BB01 CC21 GG01 GG41 4C086 AA01 AA02 DA11 MA17 MA35 NA05 ZA66 ZC37 4C088 AB18 AB21 AB38 AB62 AB81 AC05 AC11 BA06 BA10 CA03 MA17 MA35 MA52 NA05 ZA66 ZC37

Claims (11)

[Claims] 1. A medicinal composition comprising a sorghum or an extract thereof, an psyllium or an extract thereof, an aulen or an extract thereof, turmeric or an extract thereof, and a ginger or an extract thereof. 2. The pharmaceutical composition according to claim 1, further comprising carrot or an extract thereof. 3. The pharmaceutical composition according to claim 1, which further contains bile acid. 4. The pharmaceutical composition according to claim 3, wherein the bile acid is ursodeoxycholic acid. 5. The pharmaceutical composition according to any one of claims 1 to 4, wherein a part or all of Oataku and Oren are replaced by Colombo. 6. The pharmaceutical composition according to claim 1, which is a composition for gastrointestinal diseases. 7. The pharmaceutical composition according to any one of claims 1 to 5, which is a composition for preventing and treating hangover. 8. The pharmaceutical composition according to claim 1, which is a composition for promoting alcohol disappearance. 9. The pharmaceutical composition according to claim 1, which is a composition for suppressing a decrease in blood glucose level due to alcohol intake. 10. The pharmaceutical composition according to claim 1, wherein the dosage form is an oral administration preparation. 11. The pharmaceutical composition according to claim 1, wherein the dosage form is a liquid or a pill.